Perspectum secures $36m in Series C funding led by Oppenheimer Holdings to expand US operations
The medtech firm has raised $36m in a round led by Oppenheimer Holdings to accelerate its product pipeline and scale American operations.
≈ £29.8M at $1 = £0.8269 on 6 Jan 2023
A medical technology company developing advanced digital tools and artificial intelligence software to improve the diagnosis of metabolic diseases, cancer, and inflammatory conditions. Its technology enhances standard magnetic resonance imaging machines to provide quantitative assessments of organ health as non-invasive alternatives to biopsies.
Perspectum has secured $36m in the first close of its Series C funding round, led by Oppenheimer Holdings, with participation from British Patient Capital. The capital brings the company's total funding to $120m.
The Oxford-based medtech firm will direct the new capital towards scaling its operations in the United States and accelerating its product pipeline for oncology and multiorgan inflammatory conditions. Founded in 2012, the company creates digital technologies that enhance standard MRI scans to measure organ inflammation with greater precision.
The funding announcement follows a recent collaboration with Nuance Communications to distribute its quantitative magnetic resonance software across American healthcare facilities.
From the founder
"We are excited to have Oppenheimer and British Patient Capital join our mission to create safer and more accurate imaging technologies that will help clinicians shorten patients' diagnostic and treatment journeys,"
Rajarshi Banerjee
CEO at Perspectum
Investor perspective
"Life sciences and deep tech are two bright spots within the UK's innovation economy, and Perspectum is bringing the two together as they pioneer technological developments that are revolutionising the patient experience. Through our Future Fund: Breakthrough programme, we are excited to work with an industry-leading team at Perspectum and support their global growth ambitions,"
Catherine Lewis La Torre
CEO, British Patient Capital
Use of funds
- 01Expand into international markets
- 02Continue product development
Investors
Categories
About the company
Perspectum
Developing advanced medical imaging and artificial intelligence tools to improve the diagnosis of metabolic diseases and cancer.